Our study is unique in that we evaluated FGFR1 expression based on the intensity of FGFR1 labeling, and we observed strong FGFR1 positivity in 15.7% (30 cases) and moderate/weak FGFR1 positivity in 61.8% (118 cases) in a cohort of Korean pancreatic cancer patients. The gene discussed is FGFR1; the disease is pancreatic neoplasm.